---
title: "Wanchen Biotechnology released its performance for the first three quarters, with a net profit attributable to the parent company of 855 million yuan, an increase of 917.04%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262020448.md"
description: "Wanchen Biotechnology released its Q3 2025 report, with operating revenue for the first three quarters reaching 36.562 billion yuan, a year-on-year increase of 77.37%; net profit attributable to shareholders was 855 million yuan, a year-on-year increase of 917.04%; net profit excluding non-recurring gains and losses was 806 million yuan, a year-on-year increase of 955.27%; basic earnings per share were 4.684 yuan"
datetime: "2025-10-21T09:52:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262020448.md)
  - [en](https://longbridge.com/en/news/262020448.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262020448.md)
generator: "portal-rs"
---

# Wanchen Biotechnology released its performance for the first three quarters, with a net profit attributable to the parent company of 855 million yuan, an increase of 917.04%

According to the Zhitong Finance APP, Wanchen Biotechnology (300972.SZ) released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 36.562 billion yuan, a year-on-year increase of 77.37%. The net profit attributable to shareholders of the listed company was 855 million yuan, a year-on-year increase of 917.04%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 806 million yuan, a year-on-year increase of 955.27%. The basic earnings per share were 4.684 yuan

### Related Stocks

- [300972.CN](https://longbridge.com/en/quote/300972.CN.md)

## Related News & Research

- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)
- [18:23 ETAtrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://longbridge.com/en/news/296541925.md)
- [Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate](https://longbridge.com/en/news/296689195.md)
- [CARsgen FY26 H1 net loss narrows to RMB 70.84 million; revenue rises 21.49% to RMB 61.92 million](https://longbridge.com/en/news/296243257.md)
- [WellSpan and Johns Hopkins renew partnership for advanced cancer care access](https://longbridge.com/en/news/296596329.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**